Navigation Links
Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting

-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanism of Action and In Vitro Compatibility with other HCV Inhibitors-

NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. today announced the presentation of data validating the clinical antiviral activity of one of Achillion's NS4A antagonists, ACH-806, for the treatment of hepatitis C virus (HCV) infection at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). In three separate presentations, Achillion researchers discussed the potent antiviral activity in HCV-infected subjects, synergy with other classes of HCV inhibitors, and the unique mode of action of a NS4A antagonist. Achillion has shown that blocking NS4A, a viral protein that binds to a portion of HCV protease, inhibits HCV replication. This program is part of a collaboration and exclusive license agreement with Gilead Sciences for the research, development and commercialization of compounds for the treatment of chronic HCV.

In a late-breaker session on April 14th at 5:00 PM, John Pottage, M.D., Senior Vice President and Chief Medical Officer at Achillion, discussed clinical data in a presentation titled, "Short-term Antiviral Activity and Safety of ACH-806 (GS-9132), an NS4A Antagonist, in HCV Genotype 1 Infected Individuals." The randomized, double-blind, placebo-controlled dose-escalation trial measured the antiviral activity, safety and pharmacokinetics of 300 mg of ACH-806 or placebo, dosed orally twice daily as a monotherapy over 5 days. The mean change in HCV RNA (log10) at day 5 was a decrease of 0.91 from baseline for treated subjects versus an increase of 0.05 for control subjects. Elevations in serum creatinine (a marker of kidney function) were observed in ACH-806 treated subjects and were reversible after completion of dosing.

"This study provides the first demonstration of human antiviral a
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:12/4/2009)... U.S. Food and Drug Administration (FDA) today approved Zyprexa® ... treatment of schizophrenia and manic or mixed episodes associated ... old. ,, The updated Zyprexa label states that ... weight gain and hyperlipidemia in adolescents compared to adults ...
(Date:12/4/2009)... Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, ... related amended Disclosure Statement with the United States Bankruptcy Court ... to consider the adequacy of the Disclosure Statement is presently ... confirmation of the Plan scheduled for January 7, 2010. ,, ...
(Date:12/4/2009)... Dec. 4 Amber Pharmacy announced today that it ... Inc. (ACHC) for specialized pharmacy services. For nearly 15 ... and services to meet the unique needs of specialized ... of services to transplant programs. They work with over ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Amber Pharmacy Earns Accreditation From ACHC 2International expedition investigates climate change alternative fuels in Arctic 10842 1International expedition investigates climate change alternative fuels in Arctic 10842 2Reportlinker Adds Oncology Roadmap 3A Brand Spending Benchmarks and Market Forecast to 2013 61835 1Reportlinker Adds Oncology Roadmap 3A Brand Spending Benchmarks and Market Forecast to 2013 61835 2Reportlinker Adds Oncology Roadmap 3A Brand Spending Benchmarks and Market Forecast to 2013 61835 3Just like old times 3A Generating RNA molecules in water 10841 1
... Spine, a leading,developer of innovative spinal implants for ... that it has received CE mark,approval to market ... "We are delighted that the Physio-L(R) Artificial ... Clemow, Ph.D., President and CEO,of Nexgen Spine. "This ...
... of once-daily TMC278 in ... treatment-naive adults with HIV-1 -, ... from Tibotec,Pharmaceuticals Ltd. provides additional information on the safety ... inhibitor (NNRTI), as part of HIV,combination therapy in treatment-naive ...
Other Medicine Technology:Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008 2
(Date:12/5/2009)... effort by the National Association of Certified Professional ... Citizens for Midwifery (CfM), International Center for Traditional ... and the Midwifery Education Accreditation Council (MEAC). ... MAMA Campaign to secure federal recognition of CPMs ...
(Date:12/4/2009)... Thousands of KPMG LLP employees came together in more ... service event which combines the audit, tax and advisory firm,s ... service day reflects our firm,s long history of volunteerism. Instead ... caring to brighten the holidays for some children," said Tim ...
(Date:12/4/2009)... of America, Inc. ("HTA"), a self-managed, non-traded, real estate ... sale agreement to acquire a three building medical office ... Fort Wayne, Indiana for approximately $20,500,000. The closing ... a number of conditions. ,, The approximately 92,500 square ...
(Date:12/4/2009)... whether health care reform would control health care ... that lead through example -- delivering the best ... highest levels of efficiency. Thirty-four urban, eight children,s ... Leapfrog Top Hospitals, based on results from The ...
(Date:12/4/2009)... Working with mice, scientists at Johns Hopkins publishing in the ... protein made by a gene called "Twist" may be the ... drive aggressive, metastatic breast cancer from other breast cancer cells. ... a relatively rare subgroup of stem cells in breast tumors ...
Breaking Medicine News(10 mins):Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
... new DVD game to create awareness about the ill effects ... author. // ,The game is named as "Body Mechanics," ... game. ,The game begins with an introduction to ... requests players to join the team of superheroes to fight ...
... deprivation therapy may aggravate heart disease in patients over ... at Dana-Farber Cancer Institute. // ,ADT is one ... ,The study results were based on data from ... Although the findings need to be confirmed in clinical ...
... were reported across Paraguay in the last 24 hours, much ... last week, Paraguay's health authorities said on Wednesday. ... the epidemic to be a health emergency, despite several experts ... a viral infection spread by the Aedes Aegypti mosquito, with ...
... it has adopted a positive opinion recommending the granting ... (NVS) Vaccines and Diagnostics unit. ,Focetria ... prevention of influenza during an officially declared pandemic situation, ... is the second mock-up pandemic influenza vaccine to receive ...
... Senior people at Capital Health are extremely optimistic about the ... management //of emergency care and reduce waiting time for patients. ... been initiated to effectively manage space in the emergency rooms ... the hospital, whose job will be to manage beds for ...
... neglected tropical diseases should be given a higher priority ... ,Many people in Southeast Asia suffer from ... yaws. Dengue is emerging as another important problem in ... and ill-health and have considerable economic impact on populations ...
Other Medicine News:Health News:Benefits of ADT Against Risk of Heart Ailments 2Health News:WHO Urges Higher Priority for Neglected Diseases 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: